A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants

A Multiple-Center, Randomized, Double-blind, Multiple-Dose, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO0640796 (Oseltamivir) and Its Carboxylate Metabolite, RO0640802, Following Intravenous Administrations in Healthy Subjects

This multi-center, randomized, double-blind, multiple-dose, placebo-controlled, parallel-group study will assess the safety and PK of oseltamivir (Tamiflu) and its carboxylate metabolite, RO0640802 in healthy participants. Participants will be randomized to receive 100 milligrams (mg) oseltamivir, 200 mg oseltamivir, or placebo, all administered intravenously twice daily (BID). The anticipated time on study treatment is 5 days.

Inclusion Criteria:

• Participants with Body Mass Index (BMI) 18-34 kilograms per meter square (kg/m^2), inclusive
• Male participants who are willing to use barrier contraception for the duration of the study and for 3 months following the end of treatment
• Female participants who are of non-child bearing potential
• Female participants who are of child bearing potential utilizing two effective methods of contraception for the duration of the study and for 3 months following the end of treatment

Exclusion Criteria:

• Evidence of clinically significant disease or disorder (for example, renal, cardiac, bronchopulmonary)
• Any other condition or disease which would place the participant at undue risk, or interfere with the assessment, or with the ability of the participant to complete the study
• Clinically significant orthostatic hypotension present at screening or history of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness.
• Participants with abnormal electrocardiogram (ECG), bradycardia or mean QTc at screening
• Positive result for Hepatitis B, Hepatitis C, human immunodeficiency virus (HIV) 1 or 2 at screening
• Renal impairment
• Transplant recipients
• A known clinically relevant history of allergy or hypersensitivity
• Any clinically relevant abnormal laboratory test results
• A clinically relevant history of abuse of alcohol or other drugs of abuse
• Any major illness within 30 days prior to the screening examination
• Smoking of more than 10 cigarettes a day or an equivalent amount of tobacco in the form of cigars or pipe
• Participation in a clinical study with an investigational drug within 3 months prior to Day 1
• Donation/loss of more than 500 milliliters (mL) of blood within 3 months prior to Day 1
• Positive pregnancy test at screening or Day -1 and lactating women